ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective, Comparitive, Randomized Study of Allograft Versus Skin Substitute in Non-healing Diabetic Foot Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02870816
Recruitment Status : Recruiting
First Posted : August 17, 2016
Last Update Posted : January 3, 2018
Sponsor:
Collaborator:
Musculoskeletal Transplant Foundation
Information provided by (Responsible Party):
Professional Education and Research Institute

Brief Summary:
The purpose of this study is to determine whether amnion membrane grafts are more effective than another tissue engineered skin substitute, when used to treat diabetic foot ulcers (DFUs).

Condition or disease Intervention/treatment Phase
Diabetic Foot Ulcer Procedure: Tissue Engineered Skin Substitute Device: Offloading Procedure: Amnionic Membrane Graft Not Applicable

Detailed Description:
Diabetes affects at least 9% of the population, or approximately 29 million people in the United States. Lower extremity ulcers are a serious complication for people with diabetes. Diabetic foot-related problems are the most frequent cause of hospitalization within this group and it is estimated that the total cost for treatment ranges from $10,000 to nearly $60,000 depending on ulcer severity and clinical outcomes. While many diabetic foot ulcers are superficial and can heal with conservative treatment, many are more severe and recalcitrant to standard of care (SOC). About a quarter of individuals with diabetes will develop a chronic non-healing ulcer over their lifetime and nearly 60 of every 10,000 individuals with diabetes will undergo a lower extremity amputation. Holzer and associates conducted a retrospective analysis of the costs for lower extremity ulcers in patients with diabetes and concluded that, given the high costs associated with treating these ulcers, the development of better treatment strategies is warranted. One such development in the treatment of chronic wounds is the use of amniotic membrane grafts. These materials have been used successfully for many years in the treatment of orthopedic, plastic/reconstructive, and urological applications. Initial studies have demonstrated the great success of amnionic membrane graft in the healing of chronic diabetic foot ulcers and it is believed that these grafts may be superior to older, more common skin substitutes.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Multi-Center Comparative Study of Amniotic Membrane Wound Graft Application Versus Tissue Engineered Skin Substitute in the Management of Non Healing Diabetic Foot Ulcers
Actual Study Start Date : August 2016
Estimated Primary Completion Date : May 2018
Estimated Study Completion Date : May 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Tissue engineered skin substitute
Application of tissue engineered skin substitute with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional application of skin substitute will be applied weekly at weeks 2-11.
Procedure: Tissue Engineered Skin Substitute
Application of skin substitute and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.

Device: Offloading
Provision of offloading cast walker or similar sponsor-approved device. May convert into "instant total contact cast" and/or add felt/foam to supplement offloading.

Experimental: Amnionic membrane graft
Application of amnionic membrane graft with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional piece of amnionic membrane graft will be applied weekly at weeks 2-11
Device: Offloading
Provision of offloading cast walker or similar sponsor-approved device. May convert into "instant total contact cast" and/or add felt/foam to supplement offloading.

Procedure: Amnionic Membrane Graft
Application of amnion membrane graft and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.




Primary Outcome Measures :
  1. The number of participants out of 60 with complete healing of their diabetic foot ulcers as measured by complete epithialization of the foot wound comparing the two active treatment groups [ Time Frame: 6 weeks ]

Secondary Outcome Measures :
  1. Proportion of wounds healed [ Time Frame: 12 weeks ]
  2. Time to healing/complete closure [ Time Frame: 6 weeks ]
  3. Time to healing/complete closure [ Time Frame: 12 weeks ]
  4. Cost effectiveness of each treatment modality. [ Time Frame: 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female age 18 or older
  2. Informed consent must be obtained
  3. Patient's ulcer must be diabetic in origin and larger than 1cm2. Debridement will be done prior to randomization. Subject's informed consent for participating in this study, must be obtained prior to proceeding with sharp debridement.
  4. Patients with Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes mellitus per ADA).
  5. Ulcer must be present for a minimum of four weeks duration, with documented failure of prior treatment to heal the wound.
  6. Patient's ulcer must exhibit no clinical signs of infection.
  7. Wound must be present anatomically on the foot as defined by beginning below the malleoli of the ankle
  8. Additional wounds may be present but not within 3cm of the study wound
  9. Patient is of legal consenting age.
  10. Patient is willing to provide informed consent and is willing to participate in all procedures and follow up evaluations necessary to complete the study.
  11. Serum Creatinine less then 3.0mg/dl.
  12. HbA1c less than 12% taken prior to randomization .
  13. Patient has adequate circulation to the affected extremity, as demonstrated by one of the following within the past 90 days:

    1. Dorsum transcutaneous oxygen test (TcPO2) with results ≥30mmHg, OR
    2. ABIs with results of ≥0.7 and ≤1.2, OR
    3. Doppler arterial waveforms, which are triphasic or biphasic at the ankle of affected leg

Exclusion Criteria:

  1. Patients presenting with an ulcer probing to bone (UT Grade IIIA-D). A positive probe-to-bone will be confirmed when bone or joint can be felt with a sterile, ophthalmological probe.
  2. Patients whose index diabetic foot ulcers are greater than 25cm2.
  3. Patients considered not in reasonable metabolic control, confirmed by an HbA1c greater than 12% within previous 90 days.
  4. Patients whose serum creatinine levels are 3.0mg/dl or greater as noted by serum blood testing within the last six months.
  5. Patients with a known history of poor compliance with medical treatments.

6 Patients who are presently participating in another clinical trial.

7. Patients who are currently receiving radiation therapy or chemotherapy.

8. Patients with known or suspected local skin malignancy to the index diabetic ulcer.

9. Patients on anticoagulant medication will as in any surgical procedure, be monitored according to the protocols employed at the enrolling center.

10. Patients with uncontrolled autoimmune connective tissues diseases.

11. Non-revascularizable surgical sites.

12. Active infection at site.

13. Any pathology that would limit the blood supply and compromise healing.

14. Patients that have received a biomedical or topical growth factor for their wound within the previous 30 days.

15. Patient who are pregnant or breast feeding .

16. Patient who are taking medications that are considered immune system modulator.

17. Patient taking a cox-2 inhibitor.

18. Patient with wounds healing greater then 20% during the screening period.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02870816


Contacts
Contact: Linda Squillante 732- 661-2260 linda_squillante@mtf.org

Locations
United States, Virginia
Martinsville Research Institute Not yet recruiting
Martinsville, Virginia, United States, 24112
Contact: Luisa Hayes    540-525-5935    lhayes@periedu.com   
Shenandoah Lower Extremity Research Institute Not yet recruiting
Roanoke, Virginia, United States, 24013
Contact: Jennifer Keller    540-904-1458      
Professional Education and Research Institute Recruiting
Roanoke, Virginia, United States, 24016
Contact: Morgan Stepanek, BS, MBA    540-797-2726    mstepanek@periedu.com   
Sponsors and Collaborators
Professional Education and Research Institute
Musculoskeletal Transplant Foundation
Investigators
Study Director: Evangelia Chnari, PhD Director of Research and Development; Wound Care

Responsible Party: Professional Education and Research Institute
ClinicalTrials.gov Identifier: NCT02870816     History of Changes
Other Study ID Numbers: MTF-DFU-COMP-01
First Posted: August 17, 2016    Key Record Dates
Last Update Posted: January 3, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Diabetic Foot
Ulcer
Foot Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases